Union Haus
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Platform for Therapeutics
Union Haus is a plant biotechnology company that engineers recombinant proteins the conventional supply chain cannot deliver. Our proprietary UNIPLANT™ platform uses a single modular vector — deployed in two production modes (whole-plant for bulk; plant cell suspension culture for high-purity, GMP-compatible output) — so we switch products by swapping the genetic cargo, not rebuilding the platform. Our lead program, UH01E, is a plant-expressed EGF fused with a cell-penetrating peptide, validated across multiple stable transgenic soybean generations with a 13× expression boost and built-in transdermal delivery. The same chassis carries a pipeline spanning cosmetic actives, animal-free food proteins, therapeutic growth factors for chronic-wound care, and animal-origin-free growth factors for cell-therapy and cultivated-meat media — plant-derived, endotoxin-free, and produced at a fraction of mammalian-cell cost.
Company HQ City:
Gyeongsan-si
Company HQ State:
Gyeongsangbuk-do
Company HQ Country:
Korea, Republic of
Year Founded:
2023
Lead Product in Development:
UH01E — a plant-expressed Epidermal Growth Factor (EGF) fused with the MTD151 cell-penetrating peptide. Validated in stable transgenic soybean lines (T₂) with a 13× expression increase over baseline and transdermal delivery built into the molecule. Entry application is a premium cosmetic active; lead therapeutic development path is topical EGF for diabetic/chronic wound care, targeting the delivery bottleneck of current injection-dependent EGF therapeutics.
CEO
Bora Han, CEO
Development Phase of Lead Product
Discovery
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
June 2027
What is your next catalyst (value inflection) update?
Completion of yield scale-up via plant cell suspension culture, bringing UH01E (plant-expressed EGF) to commercial-grade production economics. This is the immediate inflection point, with a first B2B supply agreement with a Korean cosmetic manufacturer expected to follow shortly after — the deal negotiated in parallel during scale-up — and initiation of the preclinical development path for the therapeutic EGF program (UH01E-Rx) for chronic/diabetic wound care thereafter. All three milestones are targeted through end of 2027.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}